Drug Profile
GSK 2374697
Alternative Names: 2374697; GSK2374697Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Obesity in USA (SC, Injection)
- 31 Dec 2012 GlaxoSmithKline completes a phase I trial in Healthy volunteers in USA (NCT01545570)
- 30 Nov 2011 Phase-I clinical trials in Obesity in USA (SC)